Cytotoxic activity of FK973 against human oral and breast cancer cells.
FK973 (11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1, 11-diazatetracyclo [7.4.1.0.0] tetradeca-2, 4, 6-trien-6, 9-diyl diacetate), an analogue of mitomycin C (MMC), was tested against human oral squamous cancer cell lines Ca 9-22, HSC-2, HSC-3, breast adenocarcinoma cell lines MCF-7, BT-20 and breast ductal carcinoma cell line T-47D using MTT assay. FK973 showed cytotoxic effects against six tested cell lines and much wider effective dose range than MMC, adriamycin (ADM), and cisplatin (CDDP). FK973 was the most potent of the four drugs tested against the growth of the three squamous cancer cell lines derived from oral cavity. However, in breast cancer cell lines, FK973 was less potent than MMC and ADM. FK973 was time and dose dependent. The combination effects of FK973 with 5-Fluorouracil (5FU) or CDDP were synthetical. It may be a promising candidate for the treatment of oral and breast cancer.